SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

TITAN BIOTECH

BSE: 524717 11 Sep 2025
Commodities
₹ 687.5
Titan Bio-Tech Ltd. specializes in Specialty Chemicals within the Commodities sector.

TITAN BIOTECH - Share Price & Details

Market Cap
₹614.0
High /Low
1,018 / 374.0
Stock P/E
27.9
Book Value
₹186.0
Dividend Yield
0.27
ROCE
16.9
ROE
₹15.0
Face Value
10.0
PEG Ratio
-121.0
EVEBITDA
₹20.4
Debt
2.80
CMP / FCF
57.9
Debt to equity
₹0.02
NP Ann
21.5
High price all time
1,018
Piotroski score
₹5.0
Graham Number
333.0
No. Eq. Shares
0.83
Net CF
₹2.29
Net profit
22.0
Price to book value
4.01
Interest Coverage
₹36.7
Low price all time
8.57
Industry PE
33.6
Reserves
₹145
Free Cash Flow
₹11.6

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
SOUTHERN GAS LTD.NANANANA0.060.03
INDO GULF INDUSTRIES LTD.NANANANA0
TITAN BIOTECH LTD.NANANANA614.027.9
ANDHRA CEMENTS LTD.1005.8-296.2995.3-3.22613
ORIENT PAPER & INDUSTRIES LTD.2411.31339.932383.431.66043.83

Peer Comparison Chart


About TITAN BIOTECH

Titan Bio-Tech Ltd., with Security Code 524717, is a leading player in the Specialty Chemicals industry, categorized under the Commodities sector, offering Equity instruments.


Latest News

Purple Biotech Secures EU Patent Intent for NT219 Cancer Drug Combos | PPBT Stock News

(10 Sep 2025)
Purple Biotech's NT219 patent covers combinations with immunotherapies and MEK inhibitors for resistant cancers through 2036.
Read more →

$16.9M Strategic Acquisition: NKGen Biotech Gains Full Control of NK Cell Therapy Manufacturing & IP Portfolio

(09 Sep 2025)
NKGen Biotech (OTC: NKGN) has successfully completed the acquisition of a 65% controlling stake in NKMax Co., Ltd. for $16.9 million.
Read more →

$18M Financing: Purple Biotech Secures $6M Public Offering Plus $12M in Short-Term Warrant Potential

(06 Sep 2025)
Clinical-stage biotech Purple Biotech (NASDAQ: PPBT) closes offering of 6M ADSs at $1.00/share with warrants. Proceeds to advance oncology...
Read more →

$18M Financing Deal: Purple Biotech Prices Public Offering with $1.00 Warrants for Cancer Drug Development

(04 Sep 2025)
Purple Biotech (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies for tumor treatment, has announced the...
Read more →

26,000 Human Transcriptomes: Purple Biotech's Novel Cancer Drug Shows Promise in Resistant Tumors

(04 Sep 2025)
Mt. Sinai study demonstrates Purple Biotech's tri-specific antibody IM1240 induces tumor cell death in resistant head & neck cancer.
Read more →

Breakthrough 1-5pM Efficacy: Purple Biotech's Novel Triple-Action Cancer Antibody Shows Promise in TNBC

(04 Sep 2025)
Purple Biotech's IM1305 tri-specific antibody demonstrates tumor regression in TNBC with EC50 of 1-5pM. Platform targets TROP2 across breast...
Read more →

Company Updates